Long-Listed Drugs Should Be Priced Higher Than Generics: Mr Ohyagi

At a media meeting held by the Teijin Group on July 18, Shigeo Ohyagi, president of Teijin Pharma Ltd., commented on the NHI drug pricing system recently proposed by the JPMA (see pages 8-9, PHARMA JAPAN No. 2050) and reacted...read more